Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Merrell Dow/Affymax

Executive Summary

Enter strategic alliance for drug discovery, initially targeted at arthritis, cancer, and autoimmune disease, the companies announced June 13. In return for an undisclosed equity investment, milestone payments, and royalties on any resulting products, Palo Alto-based Affymax will perform drug discovery and development work using its VLSIPS screening technology. MMD indicated that, in the future, the disease targets may be expanded to include respiratory, cardiovascular and gastrointestinal products, although terms would have to be renegotiated. The deal is the first for Affymax, a privately-held startup founded in 1988 by Alejandro Zaffaroni, PhD, the founder of Alza, Syntex and DNAX.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel